… ProQR Receives Rare Pediatric Disease Designation from FDA … & CAMBRIDGE, Mass., Oct. 15, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to … children,” said Daniel de Boer, chief executive officer of ProQR. “This designation for sepofarsen underscores the …
… ProQR to Highlight a Growing Pipeline During a Research & … the Netherlands, March 01, 2016 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to … at 10am ET. Daniel de Boer, Chief Executive Officer of ProQR will also take part in an analyst led fireside chat at …
… ProQR Announces Enrollment Has Started in Global Phase 1b … LEIDEN, the Netherlands, June 26, 2015 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR) today announced that … said Daniel A. de Boer, Chief Executive Officer of ProQR. "Since the foundation of the company 3 years ago our …
LEIDEN, Netherlands & CAMBRIDGE, Mass., Dec. 04, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today announced that the U.S.
… ProQR Announces Closing of Initial Public Offering and Full … The Netherlands, Sept. 23, 2014 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR) announced today the … securities laws of any such state or jurisdiction. About ProQR We are an innovative biopharmaceutical company engaged …
… ProQR Announces Positive Top-Line Results from the Phase 1/2 … and CAMBRIDGE, Mass., Oct. 10, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to … Executive Vice President of Research & Development of ProQR, said, “We are very pleased with the data reported from …